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Abstract Cytochrome P450s (P450s) are involved in the
metabolism of arachidonic acid (ARA), and ARA metabo-
lites are associated with various cellular signaling pathways,
such as blood hemostasis and inflammation. The present
study demonstrates the expression of ARA-metabolizing
P450s in the human megakaryocytic Dami cells using re-
verse transcriptase-polymerase chain reaction (RT-PCR) and
immunublotting analysis followed by activity assays using
ARA as a substrate. In addition to the previously identified
CYP5A1, both protein and mRNAs of CYP1A1, 2U1, and
2J2 bands were detected. Ethoxyresorufin-O-deethylase
(EROD) activity was observed in Dami cells, and its activity
was significantly decreased after treatment with the P450
inhibitor SKF-525A when compared to the control groups
(60% reduction, P<0.001). CYP1A1 protein expression in
Dami cells was induced by 3-methylenecholantheren. This
increase in CYP1A1 protein level was correlated with en-
hanced EROD activity (fourfold increase vs. the control), as
well as with increased metabolites, such as 20-hydroxyeico-
satrienoic acid (20-HETE), 14, 15-EET (14-,15-epoxyeico-
satrienoic acid), and 14, 15-dihydroxyeicosatrienoic acid (14,
15-DHET). The expression of soluble epoxide hydrolase, an
enzyme responsible for the synthesis of DHETs from EETs,
was confirmed by RT-PCR. Furthermore, 15 ARA metabo-
lites, including 8,9-EET, 14,15-EET, and 20-HETE, were
detected by LC-MS/MS in ARA-treated Dami cells, and their
levels were decreased with the treatment of the SKF-525A.
The present data suggest the possibility that the P450s play a
role in the metabolism of ARA and other CYP-related sub-
strates in human megakaryocytes and that P450 expression in
megakaryocytic cell lines may predict their existences in plate-
lets with functional activities.
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Introduction
The cytochromes P450 (CYPs) constitute a superfamily of
hemoprotein enzymes (Zhu and Silverman 2008). They are
well recognized for their major roles in the synthesis, acti-
vation, and metabolism of many endogenous and xenobiotic
compounds, such as hormones, fatty acids, drugs, and car-
cinogens (Spriet et al. 2009). It has been repeatedly reported
that multiple P450s metabolize arachidonic acid (ARA)
(Devos et al. 2010; Mitra et al. 2011; Theken et al. 2011;
Xu et al. 2011). ARA is a fatty acid found in the human cell
membrane, which is the precursor of eicosanoids that play
important biological roles in the regulation of blood homeo-
stasis and inflammation process (Imig 2012). ARA metab-
olites have also been reported to be involved in bone mar-
row haematopoiesis, and its abnormal regulation has been
associated with the case of cardiovascular diseases (Lutton
et al. 1989; Abraham et al. 1991; Pfister et al. 2010). In
humans, ARA is epoxidized to epoxyeicosatrienoic acids
(EETs) by CYP2C and CYP2J subfamilies, while CYP4A,
4F, and 1A subfamilies and CYP2U1 enzyme hydroxylate
ARA to 20-HETE (Lasker et al. 2000; Pearson et al. 2009;
Devos et al. 2010). The expression of ARA-matabolizing
P450s varies among different tissues. For example, CYP2J2
is expressed in cardiac tissues more predominantly than in
other tissues (Wu et al. 1996). Furthermore, CYP2C subfam-
ily is found in significantly higher quantities in the liver and
gastrointestinal tract than in bonemarrow (Bieche et al. 2007).
These differences in ARA-metabolizing P450 expression
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levels may lead to different levels of ARA metabolites, thus
affecting tissues’ biological regulation.
Megakaryocytes are the bone marrow cells responsible for
the production of blood platelets. In humans, megakaryocytes
normally account for approximately 0.05−0.1% of all nucleated
bonemarrow cells. Eachmegakaryocyte produces 1,000–3,000
enucleate platelets through a thrombopoietin-mediated process
(Deutsch and Tomer 2006). Although thromboxane synthase
(CYP5A1) has been found to be highly expressed in megakar-
yocytes and platelets (Nakahata 2008), other P450 expressions
in megakaryocytes and their daughter platelets are, as yet,
poorly understood. Interestingly, ARA and some of its metab-
olites have been identified in platelets (Sheppard et al. 1992),
suggesting the possible presence of ARA-metabolizing P450s
in megakaryocytes. Since platelets, being cell fragments de-
rived from the precursor megakaryocytes, cannot proliferate in
the cell culture system due to a lack of nucleus, there are no cell
lines available for the molecular study of platelets. The mega-
karyocytic cell line (Dami cells) has frequently been used for
the study of platelets (Khetawat et al. 2000; Shi et al. 2010; Lev
et al. 2011).The goal of the present study was to determine
which P450s are expressed in Dami cells with the functional
activity for the metabolism of ARA.
Materials and Methods
Chemicals and reagents. Iscove's modified Dulbecco's me-
dium, Moloney Murine Leukemia Virus Reverse Transcrip-
tase, oligo(dT)18 primer, dithiothreitol (DTT), and first
strand buffer were obtained from Invitrogen (Carlsbad,
CA). D-Taq polymerase, 10× D-Taq buffer, and 2.5 mM
dNTP were purchased from Sun Gen (Daejeon, Korea).
Primary antibodies for CYP1A1, 2U1, and 2J2 and the
chemiluminescence kit were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). The primary antibody
for actin was obtained from Cell Signaling Technology
(Danvers, MA). Skimmed milk powder was obtained from
BD Biosciences (San Jose, CA). Resorufin, 7-ethoxy-
resorufin (7-ER), SKF-525, protease inhibitor cocktail, and
3-methylenecholantheren (3-MC) were obtained from Sigma
Aldrich (St. Louis, MO). Both 20-HETE and 20-HETE-d6
were obtained from Cayman (Ann Arbor, MI). All other
chemicals and organic solvents for activity assays were of
the highest grade available from commercial sources.
Cell culture. The human megakaryocytic Dami cell line was
obtained from the American Type Culture Collections
(Rockville, MD). Dami cells were cultured in Iscove's mod-
ified Dulbecco's medium supplemented with 10% fetal bo-
vine serum and 1% penicillin/streptomycin. Cultures were
maintained in a humidified atmosphere of 5% CO2 at 37°C
as previously described (Khetawat et al. 2000). Dami cells
were treated with 10 μM of 3-MC for 72 h in order to test
the induction of CYP1A1 and determine the effect of
CYP1A1 induction on ARA metabolism. For these experi-
ments, 3-MC was dissolved in dimethyl sulfoxide (DMSO),
and the final DMSO concentration in the culture medium
Table 1. PCR primer sequences and amplified product sizes for RT-PCR analysis
Gene Foreword primer (5′ to 3′) Reverse primer (5′ to 3′) Band size (bp) Reference
CYP1A1 GTAATCAGGGCCTCAAGAC GACATTGGTCACTGATACC 518 Finnstrom et al. 2001
CYP1A2 CAGAATGCCCTCAACACCTTCTCCATCG GTGATGTCCCGGACACTGTTCTTG 430 Finnstrom et al. 2001
CYP1B1 GTATATTGTTGAAGAGACAG AAAGAGGTACAACATCACCT 420 Finnstrom et al. 2001
CYP2C9 AGGAAAAGCACAACCAACCA TCTCAGGGTTGTGCTTGTC 104 Finnstrom et al. 2001
CYP2C8 AGATCAGAATTTTCTCACCC AACTTCGTGTAAGAGCAACA 158 Finnstrom et al. 2001
CYP2C19a CCACATGCCCTACACAGATG TGTAGCACAGAAGTGAGGGAAG 159
CYP2D6 AGGTGTGTCTCGAGGAGCCCATTTGGTA GCAGAAAGCCCGACTCCTCCTTCA 700 Finnstrom et al. 2001
CYP2J2 AGAAGCCCTTATCCACAT CTGAATGCGTTCCTCTAA 186 Finnstrom et al. 2001
CYP2U1 GCTCATCTCCATCGTGAC TTTCTAGGCCTCGTGACATA 320 Finnstrom et al. 2001
CYP4A11 TCCTGTCTGCCCATATCCTG CGGGCTTAGATTATGGTGCG 332 Finnstrom et al. 2001
CYP4F2 CGGAACCCATCACAACCCAGC CTGGGCCCTGCCGAGAAGGGAA 122 Finnstrom et al. 2001
CYP4F3 TGCTGCACCCAAGACATTGTG GCTCAGGGGCTCCACCCG 200 Finnstrom et al. 2001
CYP3A4 GTGTGGGGCTTTTATGATG GGCGACTTTCTTTCATCCT 558 Finnstrom et al. 2001
CYP3A5 CCACCTACCTATGATGCC TTGAAGAAGTCCTTGCGT 510 Finnstrom et al. 2001
CYP5A1a CAGATTCACACGGGAGGCA GGACCTAGGGCAGATTTGGA 342
AhRa GGACATGGGTCCACTCTAAT AGCCAGGAGGCAACTAGGAT 322
EPHX2a GAGTTGGTATTCTTGGAGG TGTTTGGATTTGCTGG 330
GAPDH GCTCACTGGCATGGCCTTCCG GTGGGCCATGAGGTCCACCAC 310 Finnstrom et al. 2001
a Gene-specific primers were designed in the present study
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was 0.1% (v/v). The control culture received the same vol-
ume of DMSO without 3-MC. After 3-MC treatment, the
cells were incubated with 100 μM ARA for 12 h (Rehfeldt
et al. 1993).
Reverse transcriptase-polymerase chain reaction. RNAs
from Dami cells, and human liver were extracted using
TRIzol reagent (Invitrogen) according to the manufacturer’s
instructions. Liver tissue samples were obtained from the
Inje Pharmacogenomics Research Center Biobank (Inje
University College of Medicine, Busan, Korea). The re-
search protocol for the usage of human liver tissues was
approved by the Institutional Review Board of Busan Paik
Hospital (Inje University, Busan, Korea). Three micrograms
of total isolated RNA was added to a reaction mixture
containing 100 pmol oligo(dT), 2.5 mM dNTP, 0.1M DTT,
5× first strand buffer, 200 U of M-MLV reverse transcriptase
and RNAase-free water for synthesis of cDNA. The reaction
mixtures were incubated at 42°C for 50 min. Next, conven-
tional PCR was performed by adding 330 ng of cDNA to a
mixture containing 10 mM dNTPs, 25 mM MgCl2, 2× D-
Taq polymerase buffer, 10 pmoles from each of the forward
and reverse primers (Table 1), and 1.5 U of D-Taq DNA
polymerase. The PCR products were separated on a 2%
agarose gel and visualized using ethidium bromide staining.
Immunoblot analysis. Dami cell cultures were centrifuged
at 1,000 rpm for 3 min. Then, lysis buffer [50 mM Tris–HCl
(pH 7.4), 150 mM NaCl, 1% NP40, 0.25% Na-
deoxycholate, and protease inhibitor cocktail] was added
to the Dami cell pellet. The mixture was vortexed vigorous-
ly, sonicated twice for 10 s, and the resulting lysate was
incubated on ice for 50 min. The lysates were stored at
−80°C until use. Then, 35 μg of protein was boiled at
95°C for 5 min with 4× loading buffer containing 0.1 M
Tris–HCl (pH 6.8), 4% sodium dodecyl sulfate (SDS), 1.5%
bromophenol blue, 20% glycerol, and 5% β-
mercaptoethanol. The denatured proteins were separated
with 12% SDS–polyacrylamide gel and then transferred to
a nitrocellulose membrane in a buffer containing 25 mM
Tris–HCl, 192 mM glycine, and 20% (v/v) methanol. The
membrane was blocked by 5% skimmed milk in Tris-
Buffered Saline supplemented with 0.1% Tween 20 solu-
tion. The membrane was probed with polyclonal goat anti-
CYP1A1 IgG and anti-CYP2U1 IgG, and monoclonal











































Figure 1. Expression profiles of P450s in Dami cells. (A) RT-PCR
was used to amplify each P450 with the specific primers listed in
Table 1. The targeted genes were amplified as a single product of the
expected size; no bands were detected in control samples in which the
PCR was performed in RNA samples without reverse transcriptase
treatment to confirm that there was no genomic DNA contamination.
Liver tissue cDNAwas used as a reference control for P450 detection.
EPHX2, epoxide hydrolase 2. (B) Detection of CYP1A1, 2U1, and 2J2
proteins in Dami cells by immunublot analysis. Total protein lysates
(35 μg) from Dami cells were loaded in each lane. Lysates prepared
from liver microsomes were used as a reference standard. The immu-
noreactivity of actin was used as a loading control. Proteins were
separated on a 13% SDS-polyacrylamide gel, transferred to nitrocellu-
lose membrane, and detected by primary antibodies against CYP1A1,
2U1, and 2J2. Protein bands were visualized by the chemilumines-
cence method.
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monoclonal rabbit anti-beta-actin IgG at 4°C overnight.
Immunoreactive proteins were detected using the enhanced
chemiluminescence method according to the manufacturer's
instruction (GE Healthcare Bio-Sciences, Buckinghamshire,
UK).
Determination of ethoxyresorufin O-deethylase activity.
Ethoxyresorufin O-deethylase (EROD) assays were
performed on Dami cells. Intact cells were incubated with
2 μg of 7-ER in a TN assay buffer [0.1 M NaCl, 50 mM Tris
(pH 7.8)] for 20 min. The amount of resorufin formed was
measured at excitation/emission wavelengths of 545/575 nm
(Perkin Elmer Victor 3V, MTX Lab Systems, Vienna, VA).
The standard curve of known concentrations of resorufin
was between 50 and 500 pmoles (Kennedy et al. 1993).
After measurement, the cells were lysed, and the protein
concentration was determined using the Bradford dye meth-
od (Martin et al. 1995). The resurfin formation was
expressed as nanomoles per minute per milligram of protein.
ARA metabolism assay. ARA metabolism in Dami cells was
investigated by incubation of 1×106 Dami cells with
100 μM ARA for 12 h (Rehfeldt et al. 1993). Cells were
then separated by centrifugation at 1,000 rpm for 3 min.
ARA metabolites were extracted from Dami cells and cell
media by ethyl acetate as previously reported (Zordoky et al.
2011). ARA and its metabolites were identified and quanti-
fied using a liquid chromatography–mass spectrometry (LC-
MS/MS) system, with some modifications on the previous
method (Shinde et al. 2012). Briefly, metabolites were sep-
arated on a reverse-phase column Atlantis dC18 (2.1 mm
i.d.×150 mm, 3 μm particle size; Waters, Ireland) with a
solvent consisting of water (A) and acetonitrile containing
0.1% formic acid (B). The flow rate of 0.25 ml/min with
gradient system was as follow: 0–5 min, 5% B; 5 min, 35%
B; 15 min, 65% B; 20 min, 75% B; 24–28 min, 100% B;
and 28.01 min, 5% B. ARA metabolites were identified
using an API 5500 mass spectrophotometer (Applied
Biosystems, Foster City, CA). Peak areas for all compounds
were integrated using Analyst software (version 1.2;
Applied Biosystems), and 20-HETE-6 (100 μg/ml) was
used as internal standard. The detection limits of 14,15-
EET, 14,15-dihydroxyeicosatrienoic acid (14,15-DHET)
and 20-HETE were 20, 10, and 20 pg/ml, respectively.
Statistical analysis. All values represent the mean±standard
deviation of triplicate reactions. Statistical significance was
analyzed using a two-tailed Student’s t test. All statistical
analyses were performed using the SAS program (version
9.1.3; SAS Institute, Cary, NC). Statistically significant
differences as compared with the control groups are repre-
sented as *P<0.05, **P<0.01, and ***P<0.001.
Results
Using reverse transcriptase-polymerase chain reaction (RT-
PCR) analysis, we screened the mRNA expression of 15
major P450s which are reported to metabolize ARA (Devos
et al. 2010; Mitra et al. 2011; Theken et al. 2011; Xu et al.
2011). The screened ARA-P450s were as follows: CYP1A1,
1A2, 1B1, 2C8, 2C9, 2C19, 2D6, 2J2, 2U1, 4A11, 4F2,
4F3, 3A4, and 3A5 in addition to CYP5A1 which is known
to be expressed in platelets. We detected mRNAs of
CYP1A1, 2U1, and 2J2 in Dami cells, as well as the
mRNA of CYP5A1 (Fig. 1). Specific amplification was
confirmed as their predicted sizes as shown in Table 1.
There were no detectable bands in the PCR reactions
performed with RNA samples that were not treated with
reverse transcriptase; these reactions served as a control to
monitor genomic DNA contamination. Immunobloting
analysis showed the detection of CYP1A1, 2U1, and 2J2
proteins, with bands size of 50–60 kDa, in Dami cells
(Fig. 1B). The detected bands were in agreement with the
theoretical size of 50–60 kDa for P450s and with the liver

























Figure 2. EROD assays in Dami cells. The intact cells were incubated
with 2 μg of 7-ER in a TN assay buffer for 20 min. The amount of
resorufin formed was measured at excitation/emission wavelengths of
545/575 nm by comparison with a standard curve of known concen-
trations of resorufin. Further details are in the “Materials and Methods”
section. EROD activity was expressed as nanomoles per minute per
milligram of protein. Statistically significant differences as compared
with the control group are indicated as ***P<0.001, based on a two-
tailed Student’s t test. Data are presented as the mean±S.D. of reactions
performed in triplicate.
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EROD assays of CYP1A1 were performed with Dami
cells. The activity of resorufin formation was 112±
10 nmol/min/mg protein. To confirm the activity of P450,
40 μM of the P450 inhibitor SKF-525A was added to the
reactions and compared with the non-SKF-525A-treated sam-
ples. Figure 2 shows that EROD activity decreased signifi-
cantly with the addition of SKF-525A to Dami cells (60%, P<
0.001) when compared to the control groups. Because
CYP1A1 (this study) and the nuclear Aryl hydrocarbon re-
ceptor (AhR) (Lindsey and Papoutsakis 2011) are both
expressed in megakaryocytes, we investigated the inducibility
of CYP1A1 in Dami cells using 3-MC which is an AhR
agonist, after confirming the expression of AhR in Dami cells
(Fig. 3A). Immunoblot analysis showed that the CYP1A1
protein level increased in Dami cells after 3-MC treatment
(Fig. 3B), and that this increased protein level correlated with
the increase in EROD activity (fourfold, P<0.001) as com-
pared with the DMSO-treated groups (Fig. 3C).
We found that 15 ARA metabolites were detected by LC-
MS/MS in Dami cells (Fig. 4), including 5-HETE, 8-HETE,
9-HETE, 11-HETE, 12-HETE, 15-HETE, 20-HETE, 11,12-
EET, 14,15-EET, 5,6-DHET, 11,12-DHET, 14,15-DHET,
leukotriene B4 (LTB4), 5,6-lipoxin A4 (LXA4), and
TXB2. Among the detected ARA metabolites in Dami cells,
20-HETE, 11,12-EET, and 14,15-EET have been reported to
be mediated through the ARA-P450-metabolizing pathway
in the kidney, liver, and vascular tissues (Lasker et al. 2000;
Pearson et al. 2009). The expression of soluble epoxide
hydrolase was confirmed by a specific RT-PCR (Fig 1A),
indicating that the generation of DHETs from EETs would
be from soluble epoxide hydrolase in Dami cells. Induction
of CYP1A1 protein by 3-MC treatment significantly in-
creased the levels of 20-HETE, 14,15-EET, and 14,15-
DHET than in the control group (Fig. 5). These ARA
metabolites were significantly reduced with the treatment
of the SKF-525A (P<0.05–0.001).
Discussion
Although ARA and its metabolites are important signal
molecules in blood hemostasis, ARA metabolism by
CYP1A1
Actin











































Figure 3. The effect of 3-MC on CYP1A1 expression and EROD
activity. (A) Detection of Ah receptor by RT-PCR analysis in Dami
cells. RT-PCR contains a set of AhR-specific primers as shown in
Table 1. A specific band of AhR is marked by the arrow (322 bp).
Liver tissue cDNA was used as a reference control. (B) Western blot
analysis of CYP1A1. Dami cells were cultured with 10 μM of 3-MC
(+3MC) for 72 h. The control group (-3MC) received the same volume
of the solvent (DMSO) without 3-MC. After 3-MC treatment, 35 μg of
total protein lysates from each group was loaded in a SDS-polyacryl-
amide gel for Western blot analysis of CYP1A1. Immunoblotting for
actin (45 kDa) was performed as an internal control. Detailed
procedures for the Western blot analysis are explained in the
“Materials and Methods” section. (C) Effect of 3-MC on the EROD
activity. EROD assay was performed in the 3-MC-treated and control
Dami cells. The intact Dami cells were incubated with 2 μg of 7-ER in
a TN assay buffer for 20 min. Details regarding the EROD assay are
explained in the “Materials and Methods” section. EROD activity was
expressed as nanomoles per minute per milligram of protein.
Statistically significant changes as compared with the DMSO treatment
group are indicated as ***P<0.001. Pairwise comparisons were
performed using a Student’s paired t test.
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P450s in megakaryocytes and megakaryocytic Dami cells
remains unclear. Megakaryocytic Dami cells have been used
to study the biological function of megakaryocytes and
platelets, because circulating platelets have no nucleus
(Khetawat et al. 2000; Lev et al. 2011; Lee et al. 2012). In
the current study, we investigated ARA-metabolizing P450s
in Dami cells. In addition to CYP5A1, we found that
CYP1A1, 2U1, and 2J2 were also expressed in Dami cells.
CYP1A1, 2U1, and 2J2 have been reported to metabolize
ARA and its derivatives (Devos et al. 2010; Gaedigk et al.
2006). Therefore, it can be suggested that these P450s may
play a role in the metabolism of ARA and its related eicos-
anoid compounds in the megakaryocytes and the platelets.
The literature reports several instances of similarities in
the P450 expression profiles of Dami cells and bone mar-
row. For example, in human bone marrows, CYP2U1 and
1A1 are expressed at high levels, but CYP3A and 2C are not
present (Bieche et al. 2007). Similarly, in this study
CYP1A1 and 2U1 were strongly expressed in Dami cells,
while CYP3A4, 3A5, 2C8, 2C9, and 2C19 were not detect-
able. The similar expression profiles of P450s in bone
marrow tissues and Dami cells may indicate that CYP2U1
and 1A1 in bone marrow could be derived, at least in part,
from megakaryocytes; however, it cannot rule out the pos-
sibility that other bone marrow cell types can also express
CYP1A1 and 2U1.
CYP1A1 expression was detected, and its expression was
induced by 3-MC in Dami cells. This increase in protein
expression correlated with the increase in EROD activity.
These results suggest that there could be variations in
CYP1A1 expression levels in megakaryocytes induced by
environmental stimuli, such as cigarette smoking and other
aromatic hydrocarbons with the potential to alter the metab-
olism of ARA as well as other CYP1A1 substrates.
CYP1A1 metabolizes some drugs, such as theophylline
and caffeine (Yang and Lee 2008; Amin et al. 2011). It is
expressed more in cancer tissues and activates pro-
carcinogenic compounds, such as polycyclic aromatic hy-
drocarbons (Levova et al. 2011). We found that EROD
activity was inhibited by 40 μM SKF-525A, confirming
that the reaction was mediated by P450s in megakaryocytic
Dami cells. Because EROD activity is mediated by the
CYP1A subfamily and CYP1B1 (Smith et al. 2011),
EROD activity in Dami cells appears to be a result of
CYP1A1. Our results showed that 14,15-EET and 14,15-
DHET were increased in Dami cells after treatment with 3-
MC. It is known that 14,15-EET is metabolized to 14, 15-
DHET by epoxide hydrolases (Seidegard et al. 1984). This
finding is consistent with a previous report that 14,15-EET
synthesis increases after induction of the CYP1A subfamily
by different AhR nuclear receptor agonists in human HepG2
cells (Diani-Moore et al. 2006). In the present study, the
expression of soluble epoxide hydrolase was evidenced in
Dami cells, and the experiment using the inhibitor of epox-
ide hydrolase enzyme would add additional information for
further translation of the metabolic fate for EETs and
DHETs. CYP4A and 4F subfamilies have been identified
as the main P450s for 20-HETE production (Lasker et al.
2000; Pearson et al. 2009), although multiple studies















































































Figure 4. Identification of
ARA metabolites in Dami cells.
The HPLC chromatogram
shows the 15 identified ARA
metabolites in Dami cells. The
cells were incubated with
100 μM ARA for 12 h. ARA
metabolites were then extracted
by ethyl acetate (pH 3−4). Ethyl
acetate was evaporated, and the
residue was dissolved in 100 μl
ethanol, followed by LC-MS/
MS screening for ARA
metabolites. Further details are
included in the “Materials and
Methods” section. 20-HETE-6
(100 μg/ml) was used as
internal standard.
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(Aboutabl et al. 2009; Arnold et al. 2010). Furthermore, the
formation of 20-HETE is inhibited by 7-ER in bone marrow
(Abraham et al. 1991). These results potentially indicate an
essential role for CYP1A1 in the formation of 20-HETE in
bone marrow. Our results showed that induction of CYP1A1
by 3-MC in Dami cells increased the metabolism of ARA to
20-HETE. These results indicate that altered levels of the
metabolite may cause variation in megakaryocyte and plate-
let functions. The relatively high expression of CYP1A1 in
megakaryocytes could increase our understanding of hema-
tologic diseases and hematotoxicity. Benzenes cause bone
marrow toxicity and hematotoxicity (Hirabayashi and Inoue
2010), and the aryl hydrocarbon receptor (AhR) was found to
mediate benzene-induced toxicity (Hayashibara et al. 2003).
The potent carcinogen 3-MC is an alkylated derivative of
benzo(a)anthracene. In this study, we confirmed the expres-
sion of AhR in Dami cells by RT-PCR and observed that 3-
MC induced CYP1A1 expression, which is predicted due to
the activation of AhR by 3-MC. Polyaromatic hydrocarbons
identified in cigarette smoke revealed to activate AhR and
induce CYP1A1 (Roth et al. 2001). Moreover, smoking
showed to increase platelet aggregation (Li et al. 2011).
Therefore, it is suggested to investigate the effect of
CYP1A1 induction on platelet aggregation variations. The
results of the present study indicate that Dami cells may be a
good cell line for studying CYP1A1 induction and metabo-
lism for human megakaryocytes and human platelets, at least
in part. Pregnane X receptor (PXR) and constitutive
androstane receptor (CAR) have been reported to be involved
in the regulation of CYP2J2 (Siest et al. 2008; Ellfolk et al.
2009). However, CAR and PXR were not detected by RT-
PCR in our hand (data not shown), prompting us to study the
induction of CYP1A1 in the present study.
CYP2U1 is an extrahepatic P450. It is expressed more in
the thyroid, brain, heart, and bone marrow than in the liver
(Karlgren et al. 2005; Dutheil et al. 2009). We found that
CYP2U1 was also expressed in Dami cells. Information on











































































































Figure 5. The effect of 3-MC on ARA metabolism in Dami cells.
Dami cells were treated with 10 μM 3-MC for 72 h. The control group
of Dami cells received the same final volume of the solvent (DMSO)
without 3-MC. After 3-MC treatment, 3-MC-treated Dami cells were
divided into two groups. One group of Dami cells (1×106 cells) was
incubated with 100 μM ARA for 12 h. The other group received
40 μM of SKF-525A in addition to ARA. ARA metabolites, 14,15-
EET (A), 14,15-DHET (B), and 20-HETE (C) were identified by LC-
MS/MS after liquid/liquid extraction by ethyl acetate. Further details
are described in the “Materials and Methods” section. The internal
standard utilized was 20-HETE-6 (100 μg/ml). Statistically significant
differences as compared with the DMSO treatment group are indicated
as *P<0.05, **P<0.01, and ***P<0.001, based on two-tailed
Student’s t tests. Data are presented as the mean±S.D. of reactions
performed in triplicate.
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is still no specific inhibitor and inducer of CYP2U1. However,
CYP2U1 metabolized ARA to 20-HETE (Devos et al. 2010),
suggesting that 20-HETE, which was detected in Dami cells,
could be produced, at least in part by CYP2U1.
CYP2J2 is highly expressed in the cardiovascular system
(Wu et al. 1996). It affects blood hemostasis via the metabo-
lism of ARA to EETs, which are known to decrease blood
pressure and to inhibit platelet aggregation (Spiecker and Liao
2006). Western blot analysis of CYP2J2 revealed one major
band with a molecular weight of 50–60 kDa in Dami cells.
However, we noticed that CYP2J2 in liver tissue was revealed
by two distinct bands.Wu et al. (1996) also showed two bands
in the liver and major one band of CYP2J2 in other tissues in
immunoblot analysis. These results may indicate that CYP2J2
in human heart, kidney, and the platelet precursor cells mega-
karyocytes share similar immunochemical reactions. CYP2J2
is suggested to contribute to the formation of epoxidation of
ARA (Wu et al. 1996). Expression of CYP2J2 in megakaryo-
cytes might play a role in the formation of ARA metabolites,
and they may be involved in the biological function of mega-
karyocytes and platelets.
In summary, we identified ARA-metabolizing P450s and
confirmed their expressions with functional activities in Dami
cells. These P450s may play important roles in the metabolism
of ARA as well as other xenobiotic compounds in megakar-
yocytes. Particularly, because CYP1A1 expression levels are
largely induced by environmental polycyclic aromatic hydro-
carbons, altered levels of CYP1A1 expression may cause
variations in CYP1A1-mediated metabolism in megakaryo-
cytes. The present information on P450 expressions in mega-
karyocytic Dami cells would further extend our knowledge on
the roles of P450s in megakaryocytes as well as platelets.
Acknowledgments We thank Ms. Woo-Young Kim and Ms. Il-Sun
Jung for their help in Western blot analysis and cell cultures. For
EROD assays, the expert technical assistance of the Department of
Parasitology, Inje University College of Medicine, Inje University is
greatly appreciated. The authors are particularly thankful for the gen-
erous help provided by Kyung-Suk Oh for ARA metabolite analysis.
This work was supported by the 2012 Inje University research grant.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
References
Aboutabl M. E.; Zordoky B. N.; El-Kadi A. O. 3-methylcholanthrene
and benzo(a)pyrene modulate cardiac cytochrome P450 gene
expression and arachidonic acid metabolism in male Sprague
Dawley rats. Br. J. Pharmacol. 158: 1808–1819; 2009.
Abraham N. G.; Feldman E.; Falck J. R.; Lutton J. D.; Schwartzman
M. L. Modulation of erythropoiesis by novel human bone marrow
cytochrome P450-dependent metabolites of arachidonic acid.
Blood 78: 1461–1466; 1991.
Amin N.; Byrne E.; Johnson J.; Chenevix-Trench G.; Walter S.; Nolte
I. M.; Vink J. M.; Rawal R.; Mangino M.; Teumer A.; Keers J. C.;
Verwoert G.; Baumeister S.; Biffar R.; Petersmann A.; Dahmen
N.; Doering A.; Isaacs A.; Broer L.; Wray N. R.; Montgomery G.
W.; Levy D.; Psaty B. M.; Gudnason V.; Chakravarti A.; Sulem P.;
Gudbjartsson D. F.; Kiemeney L. A.; Thorsteinsdottir U.;
Stefansson K.; van Rooij F. J.; Aulchenko Y. S.; Hottenga J. J.;
Rivadeneira F. R.; Hofman A.; Uitterlinden A. G.; Hammond C.
J.; Shin S. Y.; Ikram A.; Witteman J. C.; Janssens A. C.; Snieder
H.; Tiemeier H.; Wolfenbuttel B. H.; Oostra B. A.; Heath A. C.;
Wichmann E.; Spector T. D.; Grabe H. J.; Boomsma D. I.; Martin
N. G.; van Duijn C. M. Genome-wide association analysis of
coffee drinking suggests association with CYP1A1/CYP1A2
and NRCAM. Mol. Psychiatry 17: 1–14; 2011.
Arnold C.; Konkel A.; Fischer R.; Schunck W. H. Cytochrome P450-
dependent metabolism of omega-6 and omega-3 long-chain poly-
unsaturated fatty acids. Pharmacol. Rep. 62: 536–547; 2010.
Bieche I.; Narjoz C.; Asselah T.; Vacher S.; Marcellin P.; Lidereau R.;
Beaune P.; de Waziers I. Reverse transcriptase-PCR quantification
of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3
families in 22 different human tissues. Pharmacogenet.
Genomics 17: 731–742; 2007.
Deutsch V. R.; Tomer A. Megakaryocyte development and platelet
production. Br. J. Haematol. 134: 453–466; 2006.
Devos A.; Lino Cardenas C. L.; Glowacki F.; Engels A.; Lo-Guidice J.
M.; Chevalier D.; Allorge D.; Broly F.; Cauffiez C. Genetic
polymorphism of CYP2U1, a cytochrome P450 involved in fatty
acids hydroxylation. Prostaglandins Leukot. Essent. Fat. Acids
83: 105–110; 2010.
Diani-Moore S.; Papachristou F.; Labitzke E.; Rifkind A. B. Induction
of CYP1A and cyp2-mediated arachidonic acid epoxygenation
and suppression of 20-hydroxyeicosatetraenoic acid by imidazole
derivatives including the aromatase inhibitor vorozole. Drug
Metab. Dispos. 34: 1376–1385; 2006.
Dutheil F.; Dauchy S.; Diry M.; Sazdovitch V.; Cloarec O.; Mellottee
L.; Bieche I.; Ingelman-Sundberg M.; Flinois J. P.; de Waziers I.;
Beaune P.; Decleves X.; Duyckaerts C.; Loriot M. A. Xenobiotic-
metabolizing enzymes and transporters in the normal human
brain: regional and cellular mapping as a basis for putative roles
in cerebral function. Drug Metab. Dispos. 37: 1528–1538; 2009.
Ellfolk M.; Norlin M.; Gyllensten K.; Wikvall K. Regulation of human
vitamin D(3) 25-hydroxylases in dermal fibroblasts and prostate
cancer LNCaP cells. Mol. Pharmacol. 75: 1392–1399; 2009.
Finnstrom N.; Bjelfman C.; Soderstrom T. G.; Smith G.; Egevad L.;
Norlen B. J.; Wolf C. R.; Rane A. Detection of cytochrome P450
mRNA transcripts in prostate samples by RT-PCR. Eur. J. Clin.
Investig. 31: 880–886; 2001.
GaedigkA.; Baker D.W.; Totah R. A.; Gaedigk R.; Pearce R. E.; Vyhlidal
C. A.; Zeldin D. C.; Leeder J. S. Variability of CYP2J2 expression in
human fetal tissues. J. Pharmacol. Exp. Ther. 319: 523–532; 2006.
Hayashibara T.; Yamada Y.; Mori N.; Harasawa H.; Sugahara K.;
Miyanishi T.; Kamihira S.; Tomonaga M. Possible involvement
of aryl hydrocarbon receptor (AhR) in adult T-cell leukemia
(ATL) leukemogenesis: constitutive activation of AhR in ATL.
Biochem. Biophys. Res. Commun. 300: 128–134; 2003.
Hirabayashi Y.; Inoue T. Benzene-induced bone-marrow toxicity: a
hematopoietic stem-cell-specific, aryl hydrocarbon receptor-me-
diated adverse effect. Chem. Biol. Interact. 184: 252–258; 2010.
Imig J. D. Epoxides and soluble epoxide hydrolase in cardiovascular
physiology. Physiol. Rev. 92: 101–130; 2012.
Karlgren M.; Miura S.; Ingelman-Sundberg M. Novel extrahepatic
cytochrome P450s. Toxicol. Appl. Pharmacol. 207: 57–61; 2005.
Kennedy S. W.; Lorenzen A.; James C. A.; Collins B. T.
Ethoxyresorufin-O-deethylase and porphyrin analysis in chicken
P450S IN MEGAKARYOCYTIC DAMI CELLS 499
embryo hepatocyte cultures with a fluorescence multiwell plate
reader. Anal. Biochem. 211: 102–112; 1993.
Khetawat G.; Faraday N.; Nealen M. L.; Vijayan K. V.; Bolton E.;
Noga S. J.; Bray P. F. Human megakaryocytes and platelets
contain the estrogen receptor beta and androgen receptor (AR):
testosterone regulates AR expression. Blood 95: 2289–2296;
2000.
Lasker J. M.; Chen W. B.; Wolf I.; Bloswick B. P.; Wilson P. D.;
Powell P. K. Formation of 20-hydroxyeicosatetraenoic acid, a
vasoactive and natriuretic eicosanoid, in human kidney. Role of
Cyp4F2 and Cyp4A11. J. Biol. Chem. 275: 4118–4126; 2000.
Lee S. J.; Kwon J. A.; Cho S. A.; Jarrar Y. B.; Shin J. G. Effects of
testosterone and 17beta-oestradiol on expression of the G protein-
coupled receptor P2Y12 in megakaryocytic DAMI cells. Platelets
23: 579–585; 2012.
Lev P. R.; Goette N. P.; Glembotsky A. C.; Laguens R. P.; Meckert P.
M.; Salim J. P.; Heller P. G.; Pozner R. G.; Marta R. F.; Molinas F.
C. Production of functional platelet-like particles by the
megakaryoblastic DAMI cell line provides a model for platelet
biogenesis. Platelets 22: 28–38; 2011.
Levova K.; Moserova M.; Kotrbova V.; Sulc M.; Henderson C. J.;
Wolf C. R.; Phillips D. H.; Frei E.; Schmeiser H. H.; Mares J.;
Arlt V. M.; Stiborova M. Role of cytochromes P450 1A1/2 in
detoxication and activation of carcinogenic aristolochic acid I:
studies with the hepatic NADPH:cytochrome P450 reductase null
(HRN) mouse model. Toxicol. Sci. 121: 43–56; 2011.
Li W. J.; Zhang H. Y.; Miao C. L.; Tang R. B.; Du X.; Shi J. H.; Ma C.
S. Cigarette smoking inhibits the anti-platelet activity of aspirin in
patients with coronary heart disease. Chin. Med. J. 124: 1569–
1572; 2011.
Lindsey S.; Papoutsakis E. T. The aryl hydrocarbon receptor (AHR)
transcription factor regulates megakaryocytic polyploidization.
Br. J. Haematol. 152: 469–484; 2011.
Lutton J. D.; Schwartzman M. L.; Abraham N. G. Cytochrome P450
dependent arachidonic acid metabolism in hemopoietic cells. Adv.
Exp. Med. Biol. 271: 115–121; 1989.
Martin S. W.; Stevens A. J.; Brennan B. S.; Reis M. L.; Gifford L. A.;
Rowland M.; Houston J. B. Regional drug delivery I: permeabil-
ity characteristics of the rat 6-day-old air pouch model of inflam-
mation. Pharm. Res. 12: 1980–1986; 1995.
Mitra R.; Guo Z.; Milani M.; Mesaros C.; Rodriguez M.; Nguyen J.;
Luo X.; Clarke D.; Lamba J.; Schuetz E.; Donner D. B.; Puli N.;
Falck J. R.; Capdevila J.; Gupta K.; Blair I. A.; Potter D. A.
CYP3A4 mediates growth of estrogen receptor-positive breast
cancer cells in part by inducing nuclear translocation of
phospho-Stat3 through biosynthesis of (+/−)-14,15-
epoxyeicosatrienoic acid (EET). J. Biol. Chem. 286: 17543–
17559; 2011.
Nakahata N. Thromboxane A2: physiology/pathophysiology, cellular
signal transduction and pharmacology. Pharmacol. Ther. 118: 18–
35; 2008.
Pearson T.; Warren A. Y.; Barrett D. A.; Khan R. N. Detection of EETs
and HETE-generating cytochrome P-450 enzymes and the effects
of their metabolites on myometrial and vascular function. Am. J.
Physiol. Endocrinol. Metab. 297: 647–656; 2009.
Pfister S. L.; Gauthier K. M.; Campbell W. B. Vascular pharmacology
of epoxyeicosatrienoic acids. Adv. Pharmacol. 60: 27–59; 2010.
Rehfeldt W.; Resch K.; Goppelt-Struebe M. Cytosolic phospholipase
A2 from human monocytic cells: characterization of substrate
specificity and Ca(2+)-dependent membrane association.
Biochem. J. 293: 255–261; 1993.
Roth M. D.; Marques-Magallanes J. A.; Yuan M.; Sun W.; Tashkin D. P.;
HankinsonO. Induction and regulation of the carcinogen-metabolizing
enzyme CYP1A1 by marijuana smoke and delta (9)-tetrahydrocan-
nabinol. Am. J. Respir. Cell Mol. Biol. 24: 339–344; 2001.
Seidegard J.; DePierre J. W.; Pero R. W. Measurement and character-
ization of membrane-bound and soluble epoxide hydrolase activ-
ities in resting mononuclear leukocytes from human blood.
Cancer Res. 44: 3654–3660; 1984.
Sheppard K. A.; Greenberg S. M.; Funk C. D.; Romano M.; Serhan C.
N. Lipoxin generation by human megakaryocyte-induced 12-
lipoxygenase. Biochim. Biophys. Acta 1133: 223–234; 1992.
Shi X.; Cai W.; Zhou Y.; Zhang X.; Xiong L.; Li R.; Yu X.; Li W. IL-13
upregulates GPIIb expression in megakaryocytic cell lines via
STAT6. Anat. Rec. 293: 1470–1476; 2010.
Shinde D. D.; Kim K. B.; Oh K. S.; Abdalla N.; Liu K. H.; Bae S. K.;
Shon J. H.; Kim H. S.; Kim D. H.; Shin J. G. LC-MS/MS for the
simultaneous analysis of arachidonic acid and 32 related metabo-
lites in human plasma: basal plasma concentrations and aspirin-
induced changes of eicosanoids. J. Chromatogr. B Anal. Technol.
Biomed. Life Sci. 911: 113–121; 2012.
Siest G.; Jeannesson E.; Marteau J. B.; Samara A.; Marie B.; Pfister
M.; Visvikis-Siest S. Transcription factor and drug-metabolizing
enzyme gene expression in lymphocytes from healthy human
subjects. Drug Metab. Dispos. 36: 182–189; 2008.
Smith M. T.; Zhang L.; McHale C. M.; Skibola C. F.; Rappaport S. M.
Benzene, the exposome and future investigations of leukemia
etiology. Chem. Biol. Interact. 192: 155–159; 2011.
Spiecker M.; Liao J. Cytochrome P450 epoxygenase CYP2J2 and the
risk of coronary artery disease. Trends Cardiovasc. Med. 16: 204–
208; 2006.
Spriet I.; Meersseman W.; de Hoon J.; von Winckelmann S.; Wilmer
A.; Willems L. Mini-series: II. Clinical aspects. Clinically rele-
vant CYP450-mediated drug interactions in the ICU. Intensive
Care Med. 35: 603–612; 2009.
Theken K. N.; Deng Y.; Kannon M. A.; Miller T. M.; Poloyac S. M.;
Lee C. R. Activation of the acute inflammatory response alters
cytochrome P450 expression and eicosanoid metabolism. Drug
Metab. Dispos. 39: 22–29; 2011.
Wu S.; Moomaw C. R.; Tomer K. B.; Falck J. R.; Zeldin D. C.
Molecular cloning and expression of CYP2J2, a human cyto-
chrome P450 arachidonic acid epoxygenase highly expressed in
heart. J. Biol. Chem. 271: 3460–3468; 1996.
Xu X.; Zhang X. A.; Wang D. W. The roles of CYP450 epoxygenases
and metabolites, epoxyeicosatrienoic acids, in cardiovascular and
malignant diseases. Adv. Drug Deliv. Rev. 63: 597–609; 2011.
Yang S. H.; Lee M. G. Effects of cytochrome P450 (CYP) inducers and
inhibitors on ondansetron pharmacokinetics in rats: involvement
of hepatic CYP2D subfamily and 3A1/2 in ondansetron metabo-
lism. J. Pharm. Pharmacol. 60: 853–861; 2008.
Zhu Y.; Silverman R. B. Revisiting heme mechanisms. A perspective
on the mechanisms of nitric oxide synthase (NOS), heme oxy-
genase (HO), and cytochrome P450s (CYP450s). Biochemistry
47: 2231–2243; 2008.
Zordoky B. N.; Anwar-Mohamed A.; Aboutabl M. E.; El-Kadi A. O.
Acute doxorubicintoxicity differentially alters cytochrome P450
expression and arachidonic acid metabolism in rat kidney and
liver. Drug Metab. Dispos. 39: 1440–1450; 2011.
500 JARRAR ET AL.
